CVRx (NASDAQ:CVRX) Posts Earnings Results, Misses Estimates By $0.02 EPS

CVRx (NASDAQ:CVRX) announced its quarterly earnings results on Thursday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02), FiscalAI reports. The company had revenue of $13.83 million during the quarter, compared to analysts’ expectations of $13.93 million. CVRx had a negative net margin of 84.93% and a negative return on equity of 152.35%.

Here are the key takeaways from CVRx’s conference call:

• CVRx lowered its 2026 revenue outlook to $56 million–$57 million from $58 million–$60 million, after Q3 revenue fell 6.1% year over year to $13.8 million. Q4 revenue is expected to be $11.7 million–$12.7 million.
• Reimbursement delays at UnitedHealthcare, CVRx’s largest Medicare Advantage payer, were a major drag: the 30-day approval rate for cases handled by the company fell to about 12% from a 2025 high of 83%. CVRx is appealing denials, but says the process can take months and many customer-handled denials may not be appealed.
• Physician-champion turnover and uneven sales-team experience are slowing adoption; four of nine U.S. regions are struggling to match the growth of the five more tenured regions. Management cited early improvement in team stability but said the recovery will take time.
• CVRx reported progress in coverage and clinical evidence: two written Medicare Advantage policies now cover a combined 21% of those lives, and traditional Medicare claims data showed all submitted Q1 2026 claims were paid. In the REBALANCE real-world study, the indicated-patient group had sustained functional-class improvements and improved ejection fraction through 24 months.
• CVRx ended Q3 with $58.7 million in cash and said it has at least 18 months of runway, excluding potential additional ATM proceeds. It expects 2026 operating expenses of $99 million–$101 million after cost reductions, while continuing to invest in sales and reimbursement.

CVRx Stock Down 7.0%

NASDAQ CVRX traded down $0.11 on Thursday, hitting $1.47. The stock had a trading volume of 274,601 shares, compared to its average volume of 394,601. The business’s fifty day moving average price is $2.13 and its 200 day moving average price is $5.18. The company has a debt-to-equity ratio of 2.94, a current ratio of 8.04 and a quick ratio of 6.87. CVRx has a 52-week low of $1.25 and a 52-week high of $10.63. The stock has a market cap of $39.16 million, a price-to-earnings ratio of -0.74 and a beta of 0.81.

Analyst Ratings Changes

A number of brokerages recently weighed in on CVRX. Wall Street Zen upgraded CVRx from a “sell” rating to a “hold” rating in a research note on Saturday, October 10th. Lake Street Capital lowered CVRx from a “buy” rating to a “hold” rating and cut their target price for the company from $14.00 to $3.50 in a research note on Friday, August 7th. Craig Hallum downgraded shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a report on Friday, August 7th. Cantor Fitzgerald reduced their target price on shares of CVRx from $13.00 to $5.00 and set an “overweight” rating for the company in a report on Monday, August 17th. Finally, Piper Sandler lowered shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $4.30.

Insider Activity

In other CVRx news, COO Brent Binkowski acquired 26,223 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was purchased at an average price of $2.91 per share, for a total transaction of $76,308.93. Following the acquisition, the chief operating officer owned 56,514 shares in the company, valued at approximately $164,455.74. This trade represents a 86.57% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 16.60% of the company’s stock.

CVRx Company Profile

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.